The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VII.a

Cardiotoxicity

Publications

de la Brassinne Bonardeaux O, Born B, Moonen M, Lancellotti P

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer.

Journal of clinical medicine. 2023;12(21)

Calvillo-Argüelles O, Abdel-Qadir H, Suntheralingam S, Michalowska M, Amir E, Thavendiranathan P

Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.

The American journal of cardiology. 2020;125(8):1270-1275

Martinello R, Becco P, Vici P, Airoldi M, Del Mastro L, Garrone O, Barone C, Pizzuti L, D'Alonzo A, Bellini E, Milani A, Bonzano A, Montemurro F

Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.

The breast journal. 2019;25(3):444-449

Mohan N, Jiang J, Dokmanovic M, Wu WJ

Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.

Antibody therapeutics. 2018;1(1):13-17

Mantarro S, Rossi M, Bonifazi M, D'Amico R, Blandizzi C, La Vecchia C, Negri E, Moja L

Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.

Internal and emergency medicine. 2016;11(1):123-40

Pistilli B, Marcellusi A, Latini L, Accardi R, Ferretti B, Benedetti G

Cardiotoxicity related to long-term trastuzumab therapy in metastatic breast cancer: the potential role of treatment duration and cardiac risk factors.

The breast journal. 2015;21(3):318-21

Ayres LR, de Almeida Campos MS, de Oliveira Gozzo T, Martinez EZ, Ungari AQ, de Andrade JM, Pereira LR

Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital.

International journal of clinical pharmacy. 2015;37(2):365-72

Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.

Heart (British Cardiac Society). 2013;99(9):634-9

Fedele C, Riccio G, Coppola C, Barbieri A, Monti MG, Arra C, Tocchetti CG, D'Alessio G, Maurea N, De Lorenzo C

Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.

Breast cancer research and treatment. 2012;133(2):511-21

Guglin M, Hartlage G, Reynolds C, Chen R, Patel V

Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study.

Journal of cardiac failure. 2009;15(8):651-7